| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 158, Issue 1 518-526, Copyright © 1997 by American Association of Immunologists
ARTICLES |
SS Tinkle, LA Kittle, BA Schumacher and LS Newman
Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206, USA.
Chronic beryllium disease (CBD) provides a model for study of the Ag- stimulated, cell-mediated immune response that, over time, progresses to granulomatous lung disease. Using cells obtained with bronchoalveolar lavage from patients with CBD and normal individuals, we evaluated beryllium salt-stimulated T lymphocyte proliferation and production of proinflammatory cytokines. Our findings demonstrate that beryllium sulfate stimulates production of both IL-2 and IFN-gamma, not IL-4 and IL-7. We observed a brief time course for IL-2 protein (6-48 h after BeSO4 stimulation) and mRNA production (3-6 h) and a protracted time course for IFN-gamma protein (24-168 h) and mRNA (0.25-168 h). Beryllium-stimulated T lymphocyte proliferation and IFN-gamma release were only partially inhibited by neutralization of IL-2. On the basis of these findings, we hypothesized that IFN-gamma and the IL-2/IFN- gamma-inducible alpha subunit of the soluble IL-2 receptor were elevated in serum and bronchoalveolar lavage fluid of individuals with disease and were molecular markers of granulomatous disease. The data demonstrate that levels of the alpha subunit of the soluble IL-2 receptor, but not IFN-gamma, are elevated in the serum (median = 1428 U/ml; interquartile range = 823-2137 U/ml) and bronchoalveolar lavage fluid (median = 1.56 U/ml, interquartile range = 1.04-4.22 U/ml) of patients with CBD and correlate with the degree of pulmonary lymphocytosis and clinical measures of disease severity. We conclude that IL-2 and IFN-gamma are produced in the beryllium-stimulated, cell- mediated immune response with different time courses and that the alpha subunit of the soluble IL-2 receptor may serve as a biomarker of disease progression.
This article has been cited by other articles:
|
|
 |
|
  D. G. Mack, A. K. Lanham, B. E. Palmer, L. A. Maier, T. H. Watts, and A. P. Fontenot 4-1BB Enhances Proliferation of Beryllium-Specific T Cells in the Lung of Subjects with Chronic Beryllium Disease J. Immunol., September 15, 2008; 181(6): 4381 - 4388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Palmer, D. G. Mack, A. K. Martin, M. Gillespie, M. M. Mroz, L. A. Maier, and A. P. Fontenot Up-Regulation of Programmed Death-1 Expression on Beryllium-Specific CD4+ T Cells in Chronic Beryllium Disease J. Immunol., February 15, 2008; 180(4): 2704 - 2712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Sawyer, A. P. Fontenot, T. A. Barnes, C. E. Parsons, B. C. Tooker, L. A. Maier, M. M. Gillespie, E. B. Gottschall, L. Silveira, J. Hagman, et al. Beryllium-Induced TNF-{alpha} Production Is Transcription-Dependent in Chronic Beryllium Disease Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 191 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Chou, D. M. Edwards, A. D. Weinberg, A. A. Vandenbark, B. L. Kotzin, A. P. Fontenot, and G. G. Burrows Activation Pathways Implicate Anti-HLA-DP and Anti-LFA-1 Antibodies as Lead Candidates for Intervention in Chronic Berylliosis J. Immunol., April 1, 2005; 174(7): 4316 - 4324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Sawyer, C. E. Parsons, A. P. Fontenot, L. A. Maier, M. M. Gillespie, E. B. Gottschall, L. Silveira, and L. S. Newman Beryllium-Induced Tumor Necrosis Factor-{alpha} Production by CD4+ T Cells Is Mediated by HLA-DP Am. J. Respir. Cell Mol. Biol., July 1, 2004; 31(1): 122 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Amicosante, F. Berretta, A. Franchi, P. Rogliani, C. Dotti, M. Losi, R. Dweik, and C. Saltini HLA-DP-unrestricted TNF-{alpha} release in beryllium-stimulated peripheral blood mononuclear cells Eur. Respir. J., November 1, 2002; 20(5): 1174 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Saltini, L. Richeldi, M. Losi, M. Amicosante, C. Voorter, E. van den Berg-Loonen, R.A. Dweik, H.P. Wiedemann, D.C. Deubner, and C. Tinelli Major histocompatibility locus genetic markers of beryllium sensitization and disease Eur. Respir. J., October 1, 2001; 18(4): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. MAIER, R. T. SAWYER, R. A. BAUER, L. A. KITTLE, P. LYMPANY, D. MCGRATH, R. DUBOIS, E. DANILOFF, C. S. ROSE, and L. S. NEWMAN High Beryllium-stimulated TNF-alpha Is Associated with the -308 TNF-alpha Promoter Polymorphism and with Clinical Severity in Chronic Beryllium Disease Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1192 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Chen, B. M. Greenlee, M. Wills-Karp, and D. R. Moller Attenuation of Lung Inflammation and Fibrosis in Interferon-{gamma}-Deficient Mice after Intratracheal Bleomycin Am. J. Respir. Cell Mol. Biol., May 1, 2001; 24(5): 545 - 555. [Abstract] [Full Text]
|
|
|
|
|
|
L.A. Maier, R.T. Sawyer, S.S. Tinkle, L.A. Kittle, E.A. Barker, R. Balkissoon, C. Rose, and L.S. Newman IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis Eur. Respir. J., March 1, 2001; 17(3): 403 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lombardi, C. Germain, J. Uren, M. T. Fiorillo, R. M. du Bois, W. Jones-Williams, C. Saltini, R. Sorrentino, and R. Lechler HLA-DP Allele-Specific T Cell Responses to Beryllium Account for DP-Associated Susceptibility to Chronic Beryllium Disease J. Immunol., March 1, 2001; 166(5): 3549 - 3555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Lee, O. Atochina, B. King, L. Taylor, M. Elloso, P. Scott, and M. D. Rossman Beryllium, an Adjuvant That Promotes Gamma Interferon Production Infect. Immun., July 1, 2000; 68(7): 4032 - 4039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H-A Kim, Y Heo, S-Y Oh, K-J Lee, and D A Lawrence Altered serum cytokine and immunoglobulin levels in the workers exposed to antimony Human and Experimental Toxicology, October 1, 1999; 18(10): 607 - 613. [Abstract] [PDF]
|
|
|
|
|
|
S. S. Tinkle, L. A. Kittle, and L. S. Newman Partial IL-10 Inhibition of the Cell-Mediated Immune Response in Chronic Beryllium Disease J. Immunol., September 1, 1999; 163(5): 2747 - 2753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Fontenot, M. T. Falta, B. M. Freed, L. S. Newman, and B. L. Kotzin Identification of Pathogenic T Cells in Patients with Beryllium-Induced Lung Disease J. Immunol., July 15, 1999; 163(2): 1019 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. A. COMHAIR, M. J. LEWIS, P. R. BHATHENA, J. P. HAMMEL, and S. C. ERZURUM Increased Glutathione and Glutathione Peroxidase in Lungs of Individuals with Chronic Beryllium Disease Am. J. Respir. Crit. Care Med., June 1, 1999; 159(6): 1824 - 1829. [Abstract] [Full Text]
|
|
|
|
|
|
L. A. MAIER, M. V. RAYNOLDS, D. A. YOUNG, E. A. BARKER, and L. S. NEWMAN Angiotensin-1 Converting Enzyme Polymorphisms in Chronic Beryllium Disease Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): 1342 - 1350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Fontenot, B. L. Kotzin, C. E. Comment, and L. S. Newman Expansions of T-cell Subsets Expressing Particular T-cell Receptor Variable Regions in Chronic Beryllium Disease Am. J. Respir. Cell Mol. Biol., April 1, 1998; 18(4): 581 - 589. [Abstract] [Full Text]
|
|
|
|
|
|
S. Tinkle and L. Newman Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease Am. J. Respir. Crit. Care Med., December 1, 1997; 156(6): 1884 - 1891. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. S. Newman, C. S. Rose, and L. A. Maier Sarcoidosis N. Engl. J. Med., April 24, 1997; 336(17): 1224 - 1234. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
